Breaking News

Evotec, Eternygen Enter Metabolic Discovery Pact

May 6, 2014

Evotec will employ its drug discovery platform to identify a clinical candidate

Evotec AG and Eternygen GmbH have entered a drug discovery collaboration to develop small molecule inhibitors against an Eternygen target to treat metabolic diseases using Evotec's technology platform. Eternygen is developing the novel target, sodium coupled citrate transporter NaCT, a key regulator of energy metabolism involved in diabetes and obesity. Evotec will use its drug discovery platform to discover and develop a suitable clinical candidate.
 
Marco Janezic, chief executive officer of Eternygen GmbH, said, "Evotec as a world-leading provider for drug discovery and development services and its deep expertise in the area of metabolic diseases is the optimal partner for
Eternygen as a project focused company to drive the development process as fast as possible until proof of concept."
 
Dr. Mario Polywka, chief operating officer of Evotec, said, "We are pleased to enter this collaboration with Eternygen and we are confident that the combination of Eternygen's and our expertise in metabolic drug discovery and development will lead to success."

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Major Regulatory Changes in China to Impact Western Drug Developers

    Major Regulatory Changes in China to Impact Western Drug Developers

    David Deere, PaizaBio||January 28, 2016
    PaizaBio reports on drug development and manufacturing strategies

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.